QinetiQ and Quaisr to partner
QinetiQ and Quaisr to explore innovative materials for defence and security applications under Dstl framework partnership.
Quaisr is partnering with Multiwave Technologies and the OMICSENS consortium to develop a new omics measurement platform aimed at improving prognosis for non-small cell lung cancer (NSCLC).
As part of this European Innovation Council–funded initiative, Quaisr will deploy scalable platform infrastructure to support advanced machine-learning pipelines. These pipelines will be used by the consortium for analyte identification and quantification, enabling more precise and data-driven insights into NSCLC.
The collaboration brings together expertise in digital twins, omics technologies, and AI-driven analytics to accelerate translational research and improve clinical decision-making.
Full information: omicsens.eu
Announcement: LinkedIn
- Development of an omics measurement platform focused on NSCLC prognosis. - Deployment of Quaisr’s infrastructure for machine-learning pipelines. - Collaboration with Multiwave Technologies and the OMICSENS consortium under the European Innovation Council framework. - Application of digital twins and advanced analytics to support better clinical decision-making.
Resources
Explore more insights and resources related to this topic. Discover how AI and automation are transforming industries across the board.
Schedule a technical deep-dive to discuss your specific simulation stack, HPC security requirements, and data protocols. See exactly how Quaisr fits into your existing architecture.
Schedule a technical deep-dive to discuss your specific simulation stack, HPC security requirements, and data protocols. See exactly how Quaisr fits into your existing architecture.